en
Scientific article
English

Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse

Published inJAMA Oncology, vol. 4, no. 9, p. 1245-1253
Publication date2018
Abstract

The optimal treatment approach to patients with acute myeloid leukemia (AML) who relapse after an allogeneic hematopoietic cell transplant (allo-HCT) remains elusive. No randomized clinical trial comparing survival outcomes of a second allo-HCT (allo-HCT2) vs donor lymphocyte infusion (DLI) has been conducted to date.

Citation (ISO format)
KHARFAN-DABAJA, Mohamed A et al. Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. In: JAMA Oncology, 2018, vol. 4, n° 9, p. 1245–1253. doi: 10.1001/jamaoncol.2018.2091
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal2374-2437
282views
0downloads

Technical informations

Creation11/23/2018 2:43:00 PM
First validation11/23/2018 2:43:00 PM
Update time03/15/2023 4:03:58 PM
Status update03/15/2023 4:03:57 PM
Last indexation01/17/2024 5:13:08 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack